The Activity of TroVax® Versus Placebo in Relapsed Asymptomatic Ovarian Cancer - Full Text View - ClinicalTrials.gov
The Activity of TroVax® Versus Placebo in Relapsed Asymptomatic Ovarian Cancer (TRIOC)
This study is not yet open for participant recruitment.
Verified March 2012 by University College, London
First Received on March 14, 2012.
Last Updated on March 27, 2012
History of Changes
| Sponsor: | University College, London |
|---|---|
| Collaborators: | Oxford BioMedica Cancer Research UK |
| Information provided by (Responsible Party): | University College, London |
| ClinicalTrials.gov Identifier: | NCT01556841 |
Purpose
The
purpose of this trial is to assess the effectiveness of TroVax® compared
to placebo in extending the time to progression in patients with
asymptomatic relapsed platinum resistant ovarian, fallopian tube or primary peritoneal cancer.The trial will also look at overall survival times and quality of life.
